See more : Yueyang Forest & Paper Co., Ltd. (600963.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Coloplast A/S (COLO-B.CO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Coloplast A/S, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- LiNiu Technology Group (LINUF) Income Statement Analysis – Financial Results
- Anadolu Anonim Türk Sigorta Sirketi (ANSGR.IS) Income Statement Analysis – Financial Results
- Vert Infrastructure Ltd. (CRXPF) Income Statement Analysis – Financial Results
- Lifestyle International Holdings Limited (LFSYF) Income Statement Analysis – Financial Results
- Weimob Inc. (2013.HK) Income Statement Analysis – Financial Results
Coloplast A/S (COLO-B.CO)
About Coloplast A/S
Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.03B | 24.50B | 22.58B | 19.43B | 18.54B | 17.94B | 16.45B | 15.53B | 14.68B | 13.91B | 12.43B | 11.64B | 11.02B | 10.17B | 9.54B | 8.82B | 8.46B | 8.04B | 6.71B | 6.23B | 6.07B | 5.67B | 5.62B |
| Cost of Revenue | 9.55B | 8.17B | 7.05B | 6.11B | 5.93B | 5.79B | 5.38B | 4.96B | 4.65B | 4.38B | 3.89B | 3.77B | 3.68B | 3.60B | 3.69B | 3.72B | 3.47B | 1.95B | 1.69B | 2.44B | 2.34B | 2.16B | 2.21B |
| Gross Profit | 17.49B | 16.33B | 15.53B | 13.31B | 12.61B | 12.15B | 11.07B | 10.57B | 10.03B | 9.53B | 8.54B | 7.87B | 7.35B | 6.57B | 5.84B | 5.10B | 5.00B | 6.10B | 5.02B | 3.79B | 3.74B | 3.51B | 3.41B |
| Gross Profit Ratio | 64.69% | 66.64% | 68.78% | 68.53% | 68.01% | 67.75% | 67.27% | 68.08% | 68.33% | 68.54% | 68.70% | 67.61% | 66.63% | 64.57% | 61.28% | 57.86% | 59.06% | 75.81% | 74.85% | 60.80% | 61.52% | 61.95% | 60.69% |
| Research & Development | 866.00M | 872.00M | 866.00M | 755.00M | 708.00M | 692.00M | 640.00M | 574.00M | 509.00M | 442.00M | 390.00M | 380.00M | 342.00M | 415.00M | 409.00M | 389.00M | 415.00M | 135.00M | 97.00M | 215.00M | 200.92M | 168.00M | 173.00M |
| General & Administrative | 1.24B | 1.12B | 1.01B | 762.00M | 762.00M | 757.00M | 653.00M | 623.00M | 561.00M | 600.00M | 498.00M | 533.00M | 622.00M | 604.00M | 557.00M | 614.00M | 882.00M | -809.00M | -722.00M | -1.16B | 721.84M | 727.00M | 751.00M |
| Selling & Marketing | 8.83B | 7.52B | 6.80B | 5.49B | 5.32B | 5.21B | 4.72B | 4.37B | 4.13B | 3.96B | 3.52B | 3.31B | 3.17B | 2.99B | 2.82B | 2.69B | 2.59B | 1.22B | 1.02B | 1.85B | 1.83B | 1.67B | 1.62B |
| SG&A | 9.33B | 8.63B | 7.80B | 6.25B | 6.08B | 5.96B | 5.37B | 4.99B | 4.69B | 4.56B | 4.02B | 3.85B | 3.79B | 3.59B | 3.37B | 3.30B | 3.47B | 410.00M | 299.00M | 694.00M | 2.55B | 2.40B | 2.37B |
| Other Expenses | -33.00M | -34.00M | -49.00M | -44.00M | -29.00M | -58.00M | -39.00M | -21.00M | -15.00M | -6.00M | -16.00M | -31.00M | -46.00M | -20.00M | -17.00M | 20.00M | -85.00M | 4.80B | 3.69B | 1.85B | -148.83M | 16.00M | -44.00M |
| Operating Expenses | 10.95B | 9.48B | 8.62B | 6.96B | 6.76B | 6.60B | 5.98B | 5.55B | 5.19B | 5.00B | 4.39B | 4.19B | 4.09B | 3.99B | 3.77B | 3.71B | 3.80B | 5.35B | 4.08B | 2.76B | 2.60B | 2.58B | 2.50B |
| Cost & Expenses | 19.71B | 17.66B | 15.67B | 13.07B | 12.69B | 12.38B | 11.36B | 10.50B | 9.84B | 9.37B | 8.28B | 7.96B | 7.77B | 7.59B | 7.46B | 7.43B | 7.27B | 7.29B | 5.77B | 5.21B | 4.94B | 4.74B | 4.71B |
| Interest Income | 155.00M | 111.00M | 12.00M | 11.00M | 8.00M | 19.00M | 10.00M | 20.00M | 29.00M | 13.00M | 41.00M | 23.00M | 42.00M | 47.00M | 18.00M | 61.00M | 201.00M | 20.00M | 25.00M | 34.00M | 44.65M | 256.00M | 126.00M |
| Interest Expense | 882.00M | 638.00M | 172.00M | 25.00M | 30.00M | 6.00M | 12.00M | 12.00M | 9.00M | 5.00M | 3.00M | 49.00M | 342.00M | 171.00M | 339.00M | 245.00M | 203.00M | 184.00M | 155.00M | 156.00M | 132.00M | 310.00M | 229.00M |
| Depreciation & Amortization | 1.29B | 1.07B | 930.00M | 792.00M | 851.00M | 651.00M | 624.00M | 611.00M | 528.00M | 485.00M | 1.43B | 427.00M | 542.00M | 573.00M | 690.00M | 610.00M | 740.00M | 871.00M | 430.00M | 416.00M | 133.95M | 555.00M | 309.00M |
| EBITDA | 8.48B | 7.81B | 7.30B | 7.08B | 6.38B | 5.73B | 5.68B | 5.61B | 4.65B | 1.76B | 3.64B | 4.16B | 3.55B | 3.10B | 2.60B | 1.92B | 1.71B | 1.34B | 1.24B | 1.34B | 1.13B | 1.49B | 1.77B |
| EBITDA Ratio | 31.37% | 31.55% | 34.83% | 37.23% | 34.75% | 34.63% | 33.79% | 35.56% | 36.33% | 35.96% | 36.79% | 35.23% | 34.45% | 31.01% | 28.15% | 22.73% | 20.49% | 20.14% | 19.51% | 22.72% | 18.63% | 26.21% | 31.54% |
| Operating Income | 7.32B | 6.77B | 6.44B | 6.36B | 5.85B | 5.16B | 5.09B | 5.02B | 4.10B | 4.52B | 3.15B | 3.67B | 3.26B | 2.58B | 2.00B | 1.40B | 994.00M | 749.00M | 879.00M | 1.00B | 997.18M | 931.00M | 1.47B |
| Operating Income Ratio | 27.08% | 27.64% | 28.52% | 32.71% | 31.57% | 28.74% | 30.95% | 32.35% | 27.90% | 32.47% | 25.32% | 31.56% | 29.53% | 25.37% | 20.92% | 15.82% | 11.75% | 9.31% | 13.10% | 16.05% | 16.42% | 16.42% | 26.05% |
| Total Other Income/Expenses | -925.00M | -746.00M | -312.00M | 78.00M | -388.00M | -128.00M | -82.00M | -74.00M | -14.00M | -290.00M | 44.00M | -47.00M | -301.00M | -125.00M | -357.00M | -184.00M | -2.00M | -154.00M | -222.00M | -163.00M | -89.30M | -39.97M | 318.00M |
| Income Before Tax | 6.40B | 6.03B | 6.13B | 6.23B | 5.47B | 5.03B | 5.01B | 4.95B | 4.08B | 1.25B | 3.19B | 3.63B | 2.95B | 2.46B | 1.67B | 1.21B | 992.00M | 595.00M | 657.00M | 837.00M | 907.88M | 878.00M | 1.24B |
| Income Before Tax Ratio | 23.66% | 24.59% | 27.14% | 32.09% | 29.48% | 28.03% | 30.45% | 31.88% | 27.80% | 8.95% | 25.68% | 31.16% | 26.80% | 24.14% | 17.55% | 13.73% | 11.72% | 7.40% | 9.79% | 13.43% | 14.95% | 15.49% | 21.98% |
| Income Tax Expense | 1.34B | 1.24B | 1.42B | 1.41B | 1.27B | 1.16B | 1.16B | 1.15B | 939.00M | 346.00M | 801.00M | 914.00M | 760.00M | 637.00M | 431.00M | 328.00M | 277.00M | 225.00M | 191.00M | 272.00M | 319.99M | 297.00M | 341.00M |
| Net Income | 5.05B | 4.78B | 4.71B | 4.83B | 4.20B | 3.87B | 3.85B | 3.80B | 3.14B | 899.00M | 2.39B | 2.71B | 2.19B | 1.82B | 1.24B | 883.00M | 715.00M | 370.00M | 466.00M | 553.00M | 587.89M | 561.00M | 768.00M |
| Net Income Ratio | 18.69% | 19.52% | 20.84% | 24.84% | 22.63% | 21.59% | 23.38% | 24.45% | 21.41% | 6.46% | 19.23% | 23.30% | 19.90% | 17.88% | 13.03% | 10.01% | 8.45% | 4.60% | 6.95% | 8.87% | 9.68% | 9.90% | 13.66% |
| EPS | 22.46 | 22.21 | 22.15 | 22.67 | 19.74 | 18.24 | 18.12 | 17.91 | 14.85 | 4.30 | 11.30 | 12.90 | 10.40 | 8.60 | 5.80 | 4.20 | 3.20 | 1.62 | 2.01 | 2.40 | 1.86 | 1.78 | 3.27 |
| EPS Diluted | 22.46 | 22.19 | 22.11 | 22.63 | 19.68 | 18.17 | 18.10 | 17.87 | 14.78 | 4.20 | 11.20 | 12.60 | 10.30 | 8.60 | 5.80 | 4.20 | 3.20 | 1.62 | 1.97 | 2.40 | 1.86 | 1.78 | 3.27 |
| Weighted Avg Shares Out | 224.90M | 215.40M | 212.50M | 212.80M | 212.60M | 212.30M | 212.20M | 212.20M | 211.70M | 211.30M | 210.80M | 210.60M | 210.20M | 210.00M | 213.00M | 213.00M | 218.00M | 228.00M | 231.50M | 234.00M | 234.00M | 235.00M | 235.00M |
| Weighted Avg Shares Out (Dil) | 224.90M | 215.50M | 212.80M | 213.20M | 213.30M | 213.10M | 212.40M | 212.50M | 212.50M | 212.90M | 213.39M | 215.16M | 213.01M | 210.00M | 213.00M | 213.00M | 218.00M | 228.00M | 236.15M | 234.00M | 234.00M | 235.00M | 235.00M |
Source: https://incomestatements.info
Category: Stock Reports